Patents by Inventor Elizabeth A. McFaddin

Elizabeth A. McFaddin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors
    Patent number: 11998545
    Abstract: Provided herein are compounds of the Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which A, B, X1, X2, X3, X4, Ring D, and E have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.
    Type: Grant
    Filed: June 27, 2023
    Date of Patent: June 4, 2024
    Assignee: Array Biopharma Inc.
    Inventors: Steven W. Andrews, Sean Aronow, James F. Blake, Barbara J. Brandhuber, Adam Cook, Julia Haas, Yutong Jiang, Gabrielle R. Kolakowski, Elizabeth A. McFaddin, Megan L. McKenney, Oren T. McNulty, Andrew T. Metcalf, David A. Moreno, Tony P. Tang, Li Ren
  • RET kinase inhibitors
    Patent number: 11970485
    Abstract: Disclosed herein are compounds of formula I: or a pharmaceutically acceptable salt thereof, where the variables are as defined herein. These compounds are useful in treating RET associated cancers. Formulations containing the compounds of formula I and methods of making the compounds of formula I are also disclosed.
    Type: Grant
    Filed: October 19, 2022
    Date of Patent: April 30, 2024
    Assignee: ELI LILLY AND COMPANY
    Inventors: Gabrielle R. Kolakowski, Erin D. Anderson, Steven W. Andrews, Christopher Pierre Albert Jean Boldron, Kevin R. Condroski, Thomas C. Irvin, Manoj Kumar, Elizabeth A. McFaddin, Megan L. McKenney, Johnathan Alexander McLean, Tiphaine Mouret, Michael J. Munchhof, Thomas Pierre Dino Pancaldi, Michael Alexander Pilkington-Miksa, Marta Pinto
  • Compounds useful for inhibiting RET kinase
    Patent number: 11964968
    Abstract: Provided herein are RET kinase inhibitors according to the formula: pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, and methods for their use in the treatment of diseases that can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders. A, R1, n, X1, X2, X3, X4, and R2 have the meanings given in the specification.
    Type: Grant
    Filed: February 6, 2023
    Date of Patent: April 23, 2024
    Assignee: ELI LILLY AND COMPANY
    Inventors: Erin D. Anderson, Steven W. Andrews, Kevin R. Condroski, Thomas C. Irvin, Gabrielle R. Kolakowski, Manoj Kumar, Elizabeth A. McFaddin, Megan McKenney, Michael J. Munchhof, Michael B. Welch
  • Fused heterocyclic compounds as RET kinase inhibitors
    Patent number: 11964988
    Abstract: Provided herein are compounds of the Formula (I): (I) and tautomers, stereoisomers and pharmaceutically acceptable salts and solvates thereof, wherein Rx, Ry, W, X, Y, Z, Ring A and (AA) have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.
    Type: Grant
    Filed: September 6, 2019
    Date of Patent: April 23, 2024
    Assignee: ARRAY BIOPHARMA INC.
    Inventors: James F. Blake, Donghua Dai, Julia Haas, Yutong Jiang, Dean Kahn, Gabrielle R. Kolakowski, Elizabeth A. McFaddin, Megan L McKenney, Andrew T. Metcalf, David A. Moreno, Brett Prigaro, Ginelle A. Ramann, Li Ren, Shane M. Walls, Hailong Zhang
  • SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS
    Publication number: 20240066029
    Abstract: Provided herein are compounds of the Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which A, B, X1, X2, X3, X4, Ring D, and E have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.
    Type: Application
    Filed: June 27, 2023
    Publication date: February 29, 2024
    Inventors: Steven W. ANDREWS, Sean ARONOW, James F. Blake, Barbara J. BRANDHUBER, Adam COOK, Julia HAAS, Yutong JIANG, Gabrielle R. KOLAKOWSKI, Elizabeth A. MCFADDIN, Megan L. MCKENNEY, Oren T. MCNULTY, Andrew T. METCALF, David A. MORENO, Tony P. TANG, Li REN
  • COMPOUNDS USEFUL FOR INHIBITING RET KINASE
    Publication number: 20230312544
    Abstract: Provided herein are RET kinase inhibitors according to the formula: pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, and methods for their use in the treatment of diseases that can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders. A, R1, n, X1, X2, X3, X4, and R2 have the meanings given in the specification.
    Type: Application
    Filed: February 6, 2023
    Publication date: October 5, 2023
    Inventors: Erin D. ANDERSON, Steven W. ANDREWS, Kevin R. CONDROSKI, Thomas C. IRVIN, Gabrielle R. KOLAKOWSKI, Manoj KUMAR, Elizabeth A. MCFADDIN, Megan MCKENNEY, Michael J. MUNCHHOF, Michael B. WELCH
  • RET KINASE INHIBITORS
    Publication number: 20230265085
    Abstract: Disclosed herein are compounds of formula I: or a pharmaceutically acceptable salt thereof, where the variables are as defined herein. These compounds are useful in treating RET associated cancers. Formulations containing the compounds of formula I and methods of making the compounds of formula I are also disclosed.
    Type: Application
    Filed: October 19, 2022
    Publication date: August 24, 2023
    Inventors: Gabrielle R. KOLAKOWSKI, Erin D. ANDERSON, Steven W. ANDREWS, Christopher Pierre Albert Jean BOLDRON, Kevin R. CONDROSKI, Thomas C. IRVIN, Manoj KUMAR, Elizabeth A. MCFADDIN, Megan L. MCKENNEY, Johnathan Alexander MCLEAN, Tiphaine MOURET, Michael J. MUNCHHOF, Thomas Pierre Dino PANCALDI, Michael Alexander PILKINGTON-MIKSA, Marta PINTO
  • RET kinase inhibitors
    Patent number: 11697647
    Abstract: Disclosed herein are compounds of formula I: or a pharmaceutically acceptable salt thereof, where the variables are as defined herein. These compounds are useful in treating RET associated cancers. Formulations containing the compounds of formula I and methods of making the compounds of formula I are also disclosed.
    Type: Grant
    Filed: November 5, 2021
    Date of Patent: July 11, 2023
    Assignee: Eli Lilly and Company
    Inventors: Gabrielle R. Kolakowski, Erin D. Anderson, Steven W. Andrews, Christopher Pierre Albert Jean Boldron, Kevin R. Condroski, Thomas C. Irvin, Manoj Kumar, Elizabeth A. McFaddin, Megan L. McKenney, Johnathan Alexander McLean, Tiphaine Mouret, Michael J. Munchhof, Thomas Pierre Dino Pancaldi, Michael Alexander Pilkington-Miksa, Marta Pinto
  • Antimycobacterial heterocyclic amides
    Patent number: 11655225
    Abstract: The present invention provides novel heterocylic amide compounds having useful antimycobacterial activity. Use of these compounds as pharmaceutical compositions and method of their production are also provided.
    Type: Grant
    Filed: February 28, 2019
    Date of Patent: May 23, 2023
    Assignee: CRESTONE, INC.
    Inventors: Joshua Day, James Graham, Thale Jarvis, Elizabeth Mcfaddin, Urs Ochsner, Xicheng Sun, Christina Wong
  • Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors
    Patent number: 11648243
    Abstract: Provided herein are compounds of the Formula I: or pharmaceutically acceptable salt or solvate thereof, wherein A, B, X1, X2, X3, X4, Ring D, E, Ra, Rb, n and m have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.
    Type: Grant
    Filed: December 1, 2020
    Date of Patent: May 16, 2023
    Assignee: Array Biopharma Inc.
    Inventors: Steven W. Andrews, Sean Aronow, James F. Blake, Barbara J. Brandhuber, James Collier, Adam Cook, Julia Haas, Yutong Jiang, Gabrielle R. Kolakowski, Elizabeth A. Mcfaddin, Megan L. Mckenney, Oren T. McNulty, Andrew T. Metcalf, David A. Moreno, Ginelle A. Ramann, Tony P. Tang, Li Ren, Shane M. Walls
  • Compounds useful for inhibiting RET kinase
    Patent number: 11613533
    Abstract: Provided herein are RET kinase inhibitors according to the formula: pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, and methods for their use in the treatment of diseases that can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders. A, R1, n, X1, X2, X3, X4, and R2 have the meanings given in the specification.
    Type: Grant
    Filed: April 23, 2021
    Date of Patent: March 28, 2023
    Assignee: Eli Lilly and Company
    Inventors: Erin D. Anderson, Steven W. Andrews, Kevin R. Condroski, Thomas C. Irvin, Gabrielle R. Kolakowski, Manoj Kumar, Elizabeth A. McFaddin, Megan McKenney, Michael J. Munchhof, Michael B. Welch
  • SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS
    Publication number: 20230090520
    Abstract: Provided herein are compounds of the Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which A, B, X1, X2, X3, X4, Ring D, and E have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.
    Type: Application
    Filed: November 19, 2021
    Publication date: March 23, 2023
    Inventors: Steven W. ANDREWS, Sean ARONOW, James F. BLAKE, Barbara J. BRANDHUBER, Adam COOK, Julia HAAS, Yutong JIANG, Gabrielle R. KOLAKOWSKI, Elizabeth A. MCFADDIN, Megan L. MCKENNEY, Oren T. MCNULTY, Andrew T. METCALF, David A. MORENO, Tony P. TANG, Li REN
  • Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
    Patent number: 11603374
    Abstract: Provided herein are compounds of the Formula I: [INSERT FORMULA I] and tautomers, stereoisomers and pharmaceutically acceptable salts and solvates thereof, wherein R1, R2 and Ry have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.
    Type: Grant
    Filed: January 18, 2019
    Date of Patent: March 14, 2023
    Assignee: Array BioPharma Inc.
    Inventors: James F. Blake, Donghua Dai, Julia Haas, Yutong Jiang, Gabrielle R. Kolakowski, Elizabeth A. McFaddin, Megan L. McKenney, Andrew T. Metcalf, David A. Moreno, Brett Prigaro, Ginelle A. Ramann, Li Ren
  • Substituted pyrazolyl[4,3-c]pyridine compounds as RET kinase inhibitors
    Patent number: 11472802
    Abstract: Provided herein are compounds of the Formula I: and tautomers and pharmaceutically acceptable salts and solvates thereof, wherein R1, R2 and R3 have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.
    Type: Grant
    Filed: January 18, 2019
    Date of Patent: October 18, 2022
    Assignee: Array BioPharma Inc.
    Inventors: Shane M. Walls, Li Ren, Ginelle A. Ramann, David A. Moreno, Andrew T. Metcalf, Elizabeth A. McFaddin, Gabrielle R. Kolakowski, James F. Blake, Donghua Dai, Julia Haas, Yutong Jiang, Dean Kahn
  • SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS
    Publication number: 20220313676
    Abstract: Provided herein are compounds of the Formula I: or pharmaceutically acceptable salt or solvate thereof, wherein A, B, X1, X2, X3, X4, Ring D, E, Ra, Rb, n and m have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.
    Type: Application
    Filed: December 1, 2020
    Publication date: October 6, 2022
    Inventors: Steven W. ANDREWS, Sean ARONOW, James F. BLAKE, Barbara J. BRANDHUBER, James COLLIER, Adam COOK, Julia HAAS, Yutong JIANG, Gabrielle R. KOLAKOWSKI, Elizabeth A. MCFADDIN, Megan L. MCKENNEY, Oren T. MCNULTY, Andrew T. METCALF, David A. MORENO, Ginelle A. RAMANN, Tony P. TANG, Li REN, Shane M. WALLS
  • RET KINASE INHIBITORS
    Publication number: 20220144816
    Abstract: Disclosed herein are compounds of formula I: or a pharmaceutically acceptable salt thereof, where the variables are as defined herein. These compounds are useful in treating RET associated cancers. Formulations containing the compounds of formula I and methods of making the compounds of formula I are also disclosed.
    Type: Application
    Filed: November 5, 2021
    Publication date: May 12, 2022
    Inventors: Gabrielle R. Kolakowski, Erin D. ANDERSON, Steven W. Andrews, Christopher Pierre Albert Jean BOLDON, Kevin R. CONDROSKI, Thomas C. IRVIN, Manoj KUMAR, Elizabeth A. MCFADDIN, Megan L. MCKENNEY, Johnathan Alexander MCLEAN, Tiphaine MOURET, Michael J. MUNCHHOF, Thomas Pierre Dino PANCALDI, Michael Alexander PILKINGTON-MIKSA, Marta PINTO
  • FUSED HETEROCYCLIC COMPOUNDS AS RET KINASE INHIBITORS
    Publication number: 20220112214
    Abstract: Provided herein are compounds of the Formula (I): (I) and tautomers, stereoisomers and pharmaceutically acceptable salts and solvates thereof, wherein Rx, Ry, W, X, Y, Z, Ring A and (AA) have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.
    Type: Application
    Filed: September 6, 2019
    Publication date: April 14, 2022
    Inventors: James F. BLAKE, Donghua DAI, Julia HAAS, Yutong JIANG, Dean KAHN, Gabrielle R. KOLAKOWSKI, Elizabeth A. MCFADDIN, Megan L. MCKENNEY, Andrew T. METCALF, David A. MORENO, Brett PRIGARO, Ginelle A. RAMANN, Li REN, Shane M. WALLS, Hailong ZHANG
  • COMPOUNDS USEFUL FOR INHIBITING RET KINASE
    Publication number: 20210363140
    Abstract: Provided herein are RET kinase inhibitors according to the formula: pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, and methods for their use in the treatment of diseases that can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders. A, R1, n, X1, X2, X3, X4, and R2 have the meanings given in the specification.
    Type: Application
    Filed: April 23, 2021
    Publication date: November 25, 2021
    Inventors: Erin D. ANDERSON, Steven W. ANDREWS, Kevin R. CONDROSKI, Thomas C. IRVIN, Gabrielle R. KOLAKOWSKI, Manoj KUMAR, Elizabeth A. MCFADDIN, Megan MCKENNEY, Michael J. MUNCHHOF, Michael B. WELCH
  • SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS
    Publication number: 20210186959
    Abstract: Provided herein are compounds of the Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which A, B, X1, X2, X3, X4, Ring D, and E have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.
    Type: Application
    Filed: February 2, 2021
    Publication date: June 24, 2021
    Inventors: Steven W. Andrews, Sean Aronow, James F. Blake, Barbara J. Brandhuber, Adam Cook, Julia Haas, Yutong Jiang, Gabrielle R. Kolakowski, Elizabeth A. McFaddin, Megan L. McKenney, Oren T. McNulty, Andrew T. Metcalf, David A. Moreno, Tony P. Tang, Li Ren
  • Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors
    Patent number: 10953005
    Abstract: Provided herein are compounds of the Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which A, B, X1, X2, X3, X4, Ring D, and E have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.
    Type: Grant
    Filed: January 10, 2020
    Date of Patent: March 23, 2021
    Assignee: Array Biopharma Inc.
    Inventors: Steven W. Andrews, Sean Aronow, James F. Blake, Barbara J. Brandhuber, Adam Cook, Julia Haas, Yutong Jiang, Gabrielle R. Kolakowski, Elizabeth A. McFaddin, Megan L. McKenney, Oren T. McNulty, Andrew T. Metcalf, David A. Moreno, Tony P. Tang, Li Ren